Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Inc (NASDAQ: INSM) is a global biopharmaceutical leader developing innovative therapies for rare pulmonary diseases and chronic inflammatory conditions. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and therapeutic advancements.
Access real-time information about Insmed's FDA submissions, partnership announcements, and research breakthroughs. Our curated collection includes updates on ARIKAYCE commercialization, brensocatib clinical studies, and novel inhalation technologies like TPIP platform developments.
Key content categories include treatment approvals, scientific conference presentations, patent filings, and manufacturing expansions. All materials are sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page for streamlined access to Insmed's latest developments in targeted pulmonary therapy and rare disease research. Check regularly for critical updates affecting treatment accessibility and clinical progress.
Insmed Incorporated (Nasdaq: INSM) will announce its fourth quarter and full year 2021 financial results on February 17, 2022. Management will also provide a business and pipeline update during a conference call from 8:00 to 9:30 a.m. ET. Interested parties can join by calling specified numbers or via webcast on the company's website. A replay of the call will be available for a month. Insmed's mission is to improve lives with therapies for serious diseases, and it has a robust pipeline addressing unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 p.m. ET. The event will be available via live webcast on the company's website, with an archived version accessible for 30 days post-event. Insmed is focused on transforming the lives of patients with serious and rare diseases, notably with its first commercial product targeting a chronic lung disease and an expanding pipeline for unmet needs.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to six new employees, totaling 43,610 stock options exercisable at $26.69 per share. These options come with a ten-year term and a four-year vesting schedule, with 25% vesting after one year and the remainder vesting semi-annually thereafter. This move, compliant with NASDAQ Listing Rule 5635(c)(4), aims to attract talent into the company. Insmed focuses on treating serious and rare diseases, with an approved therapy for a chronic lung disease and a pipeline of investigational therapies.
Insmed has announced the grant of inducement awards to 15 new employees, approved by its Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 52,180 shares at an exercise price of $31.05, the closing price as of November 1, 2021. The options have a ten-year term and will vest over four years, with the first 25% vesting after one year, followed by 12.5% every six months. Insmed aims to improve the lives of patients with serious and rare diseases and continues expanding its pipeline of therapies.
Insmed Incorporated (Nasdaq: INSM) announced its participation in three upcoming virtual investor conferences aimed at discussing the company's developments in biopharmaceuticals. On November 9, 2021, at 10:30 a.m. ET, Insmed will join the Credit Suisse 30th Annual Virtual Healthcare Conference. This will be followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. ET, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 8:00 a.m. ET. All events will be webcast live and archived for 30 days.
Insmed Incorporated (Nasdaq: INSM) reported Q3 2021 revenue of $46.8 million, up from $43.6 million in Q3 2020. The company experienced a GAAP net loss of $112.7 million or $0.96 per share, widening from a loss of $63.7 million or $0.63 per share year-over-year. Key developments include strong initial uptake of ARIKAYCE in Japan and ongoing clinical trials for brensocatib and TPIP. Insmed ended the quarter with $846.6 million in cash and cash equivalents, positioning it well for future investments and growth.
Insmed Incorporated (Nasdaq:INSM) will release its third quarter 2021 financial results on October 28, 2021. A conference call will follow at 8:30 a.m. ET to discuss the results and offer a business update. Participants can join via phone or through a live webcast on the company's website. Insmed focuses on rare and serious diseases, with its first product being a therapy approved in multiple regions, including the US, Europe, and Japan. The company is also developing investigational therapies in high-need areas.
Insmed announced on October 5, 2021, that it has granted inducement awards to 11 new employees. These awards consist of options to purchase a total of 67,760 shares of common stock at an exercise price of $27.38, the closing price on the grant date. The options feature a ten-year term with a four-year vesting schedule, where 25% vests after the first year and 12.5% every six months thereafter, contingent on continued employment. This initiative is aligned with NASDAQ Listing Rule 5635(c)(4).
On September 3, 2021, Insmed announced the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 394,730 shares at an exercise price of $29.13 per share, matching the closing price on September 1, 2021. The options come with a ten-year term and a four-year vesting schedule, with 25% vesting after the first year. Insmed focuses on treating serious and rare diseases with a robust therapy pipeline alongside its first-in-disease product approved in multiple regions.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
